Protein glycosylation is a fundamental biological process that regulates various cellular functions, yet its study has been hampered by the complexity and low abundance of glycoproteins.
Conduit acquires three first-in-class assets from AstraZeneca – Pharmaceutical Technology
Conduit has acquired two HK-4 glucokinase activators—AZD1656 and AZD5658, and AZD5904, a myeloperoxidase inhibitor (MPO). Credit: PeopleImages.com – Yuri A via Shutterstock. Conduit Pharmaceuticals’ will
August 8, 2024